bearish
JNJ's REMICADE Holds: PFE's Results To Confirm
503 Views19 Jul 2017 06:14
Johnson & Johnson (JNJ US) reported Q2 2017 results today (quotes from earnings call are below). US revenue for REMICADE (reference product for...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 2-minute read)
Discussions
(Paid Plans Only)
Kemp Dolliver, CFA
Founder
Price Chart(Sign Up to Access)
- Celltrion (068270 KS): Korean Making Biological Drugs for the West05 Jan 2018
- Celltrion Has Potential Manufacturing Headaches07 Sep 2017
- Biogen Likes Biosimilars25 Jul 2017
- JNJ's REMICADE Holds: PFE's Results To Confirm19 Jul 2017
- Celltrion Healthcare IPO Part 6 - IPO Bookbuilding Results17 Jul 2017
- The Disconnect Is Growing22 Apr 2017
- Reconsider the Samsung Bioepis Valuation11 Mar 2017
x